Compare Huntington Bancshares Incorporated (HBAN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Incyte Corporation — how do they compare? Huntington Bancshares Incorporated trades at $18.13 (market cap $36.62B), while Incyte Corporation trades at $118.01 (market cap $23.11B). The key difference: Huntington Bancshares Incorporated is the larger of the two by market cap, and Huntington Bancshares Incorporated pays a 3.43% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| HBAN | INCY | |
|---|---|---|
Market Cap | $36.62B | $23.11B |
Sector | Financials | Health |
52-Week High | $19.27 | $118.52 |
52-Week Low | $15.02 | $67.38 |
Dividend Yield | 3.43% | — |
Enterprise Value | — | $19.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.07, down 0.99% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, with revenue growth to $8.13 billion in 2025. Recent news highlights expansion in Texas and a strong fintech partnership award.
HBAN presents a mixed outlook; analyst consensus is a Buy with a $20.25 price target, implying upside, but risks include integration challenges from acquisitions and competitive pressures in regional banking. Earnings growth and margin stability are key catalysts, though debt levels have risen steadily.
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
